Antrum Biotech
Antrum Biotech is a healthcare innovations company dedicated to developing rapid diagnostic platforms for infectious diseases, with a focus on improving diagnostics for tuberculosis and other pulmonary diseases, especially in high-burden, resource-poor settings. Their mission is to translate research into impactful healthcare products and to be a significant contributor to global healthcare innovation.
Industries
Nr. of Employees
small (1-50)
Antrum Biotech
H50, H Floor, Old Main Building, Groote Schuur Hospital, Observatory 7925, Cape Town, South Africa
Products
Rapid immuno-suspension diagnostic assay for extra-pulmonary tuberculosis
A rapid bead-based immunoassay designed to detect host- or pathogen-associated biomarkers in clinical samples to diagnose extra-pulmonary tuberculosis, including TB meningitis; intended to provide results in under two hours and to be compatible with standard laboratory infrastructure.
Rapid immuno-suspension diagnostic assay for extra-pulmonary tuberculosis
A rapid bead-based immunoassay designed to detect host- or pathogen-associated biomarkers in clinical samples to diagnose extra-pulmonary tuberculosis, including TB meningitis; intended to provide results in under two hours and to be compatible with standard laboratory infrastructure.
Services
Analysis of critical technical and market aspects to determine probability of project or product success.
Tissue culture-based antibody isolation and affinity chromatography for purification and custom antibody design/modification.
R&D capability to develop novel immunoassays, with specialization in ELISA and lateral-flow formats.
Analytical and performance optimization to improve sensitivity, specificity and reproducibility of immunoassay platforms, including electrochemical formats.
Process development and scale-up services to transfer analytical platforms to larger-scale production.
Rapid sample processing for human clinical samples, sample management and logistics, and on-site bio-repository capabilities to support clinical studies.
Analysis of critical technical and market aspects to determine probability of project or product success.
Tissue culture-based antibody isolation and affinity chromatography for purification and custom antibody design/modification.
R&D capability to develop novel immunoassays, with specialization in ELISA and lateral-flow formats.
Analytical and performance optimization to improve sensitivity, specificity and reproducibility of immunoassay platforms, including electrochemical formats.
Process development and scale-up services to transfer analytical platforms to larger-scale production.
Rapid sample processing for human clinical samples, sample management and logistics, and on-site bio-repository capabilities to support clinical studies.
Expertise Areas
- Rapid diagnostic development for infectious diseases
- Immunoassay design and validation
- Biomarker discovery and qualification
- Clinical sample processing and biobanking
Key Technologies
- Immunoassays (ELISA, lateral flow)
- Immuno-suspension (bead-based) assay platforms
- Electrochemical immunoassays
- Antibody purification and affinity chromatography
News & Updates
Researchers at the University of Cape Town have developed a rapid test which diagnoses various forms of Tuberculosis (TB) within hours, including TB Meningitis and extra-pulmonary TB. The test is currently undergoing validation to enter the market.
This article discusses the urgent need for improved diagnostic tools for TB meningitis, highlighting the limitations of current microbiologic and molecular tests and proposing biomarker-based testing as an adjunctive approach.
Researchers at the University of Cape Town have developed a rapid test which diagnoses various forms of Tuberculosis (TB) within hours, including TB Meningitis and extra-pulmonary TB. The test is currently undergoing validation to enter the market.
This article discusses the urgent need for improved diagnostic tools for TB meningitis, highlighting the limitations of current microbiologic and molecular tests and proposing biomarker-based testing as an adjunctive approach.